Pharmaceuticals company RPG Life Sciences announced Q1FY27 results Consolidated Financial Highlights: Revenue from Operations for Q1FY27 stood at Rs 19,569 lakh, compared to Rs 16,892 lakh in Q1FY26, reflecting a YoY increase of 15.85%. On a sequential basis, it grew by 10.63% from Rs 17,689 lakh in Q4FY26. Total Income reached Rs 20,039 lakh in Q1FY27, a YoY growth of 15.07% from Rs 17,415 lakh in Q1FY26 and a QoQ growth of 5.86% from Rs 18,929 lakh in Q4FY26. Net Profit (Profit for the period) in Q1FY27 was Rs 3,076 lakh, showing a YoY increase of 17.00% from Rs 2,629 lakh in Q1FY26 and a QoQ increase of 2.88% from Rs 2,990 lakh in Q4FY26. Profit Before Tax for Q1FY27 stood at Rs 4,146 lakh, representing a YoY growth of 17.02% from Rs 3,543 lakh in Q1FY26 and a QoQ growth of 3.13% from Rs 4,020 lakh in Q4FY26. Total Comprehensive Income for Q1FY27 was reported at Rs 3,061 lakh, up 16.48% YoY from Rs 2,628 lakh in Q1FY26 and up 2.10% QoQ from Rs 2,998 lakh in Q4FY26. Earnings Per Share (EPS) (Basic and Diluted) for Q1FY27 stood at Rs 18.60, compared to Rs 15.90 in Q1FY26 and Rs 18.08 in Q4FY26. Standalone Financial Highlights: Revenue from Operations for Q1FY27 was Rs 19,569 lakh, showing a YoY growth of 15.85% from Rs 16,892 lakh in Q1FY26 and a QoQ increase of 10.63% from Rs 17,689 lakh in Q4FY26. Total Income in Q1FY27 was Rs 19,985 lakh, a YoY increase of 14.76% from Rs 17,415 lakh in Q1FY26 and a QoQ growth of 5.60% from Rs 18,925 lakh in Q4FY26. Net Profit reached Rs 3,057 lakh in Q1FY27, reflecting a YoY increase of 16.28% from Rs 2,629 lakh in Q1FY26 and a QoQ increase of 2.24% from Rs 2,990 lakh in Q4FY26. Business Highlights: API Division Transfer: On December 15, 2025, the Board of Directors approved the transfer of the API division ("the Division") of the Company to its wholly owned subsidiary (WOS), RPG Active Pharma Limited, which was incorporated on December 24, 2025. The transaction is expected to be concluded upon receipt of requisite approvals and completion of customary conditions precedent. Impact of Insurance Settlement (FY26): During the year ended March 31, 2026, the Company received a full settlement of the insurance claim relating to a fire incident at its Navi Mumbai API plant that occurred in January 2025. This resulted in a net income of Rs 2,475 lakh, recognized as exceptional income in FY26. Labour Code Impact (FY26): The Company recognized an exceptional expense of Rs 1,169 lakh in FY26 towards the impact of the New Labour Codes notified effective November 22, 2025, primarily arising from the change in wage definition. Ashok Nair, Managing Director, RPG Life Sciences, said: “We have started FY27 on a strong note continuing our track record of market-beating performance and growth. Our Domestic Formulations business continued to outperform the market and helped the company enter the Top 50 ranking in the Indian Pharma Market, an important milestone in our growth journey. Going forward, we remain focused on strengthening our international presence through market expansion and new customer onboarding along with scaling up our API operations that can drive the next wave of growth of us. Backed by strong balance sheet, healthy profitability and continued investment in talent, we remain confident of sustaining our growth momentum in the long-term.” Result PDF